Neurotech’s NTI164 Shows Promise for Pediatric Autoimmune Disorders

Neurotech International Ltd. (AU:NTI) has released an update.

Neurotech International Ltd reports that its biological agent NTI164 has demonstrated promising effects in treating PANDAS/PANS, a pediatric autoimmune disorder, by reversing immune and gene translation dysregulation observed in a Phase I/II clinical trial. The treatment has shown potential in normalizing immune function and improving overall health outcomes in children, with additional patent applications filed based on these novel findings. The company eagerly anticipates further genomic analysis to support these results.

For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.